Ablynx identifies novel Nanobodies under P&G deal

Belgium-based Ablynx, a pioneer in the discovery and development of Nanobodies says that its collaboration agreement with Procter & Gamble Pharmaceuticals, a division of Procter & Gamble, has reached a second milestone. Ablynx has discovered novel Nanobodies against a second target for possible new treatments in the musculoskeletal area. The first milestone under this collaboration was achieved in December 2006 and was also a target for such diseases.

Ablynx says its unique and patented Nanobody technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies against one of the targets exclusive to the collaboration, triggering a second undisclosed milestone payment.